Aclaris Therapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Regulation FD Disclosure

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Results of Operations and Financial Condition

7.01,9.01

Entry into a Material Definitive Agreement

Automatic Shelf Registration

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Registration statement under Securities Act of 1933

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933

<ITEMS>06b

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Automatic Shelf Registration

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

No description available

Prospectus Supplement for Primary Offering

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Frazier Life Sciences Public Fund, L.P.

RA CAPITAL MANAGEMENT, L.P.

Kolbeck Roland Wilhelm

Mehra Anand

GOWEN MAXINE

MILANO VINCENT

SCHIFF ANDREW N

Humphries William D.

Molineaux Christopher P.

Vivo Opportunity Fund Holdings, L.P.

Hall Jesse Wayne

BML Investment Partners, L.P.

Leonard Braden Michael

RA CAPITAL MANAGEMENT, L.P.

VANGUARD GROUP INC

Deep Track Capital, LP

Balthaser Kevin

BML Investment Partners, L.P.

Loerop James

Davis Hugh M.

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

No description available

No description available

No description available

No description available

No description available

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

No description available